Drug Trial Radar · NCT04893239
Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies
Last checked: Nov 19, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Aug 18, 2021
Primary completion
Feb 23, 2022
Study completion Feb 23, 2022
Sponsor
- Lead sponsor
- Lumen Bioscience, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, single-site, open label, exploratory study to assess delivery of LMN-201 components via enteric capsules in the gut of individuals with ostomies.
Conditions
- C. Diff. Infections
Interventions
LMN-201 Anti-toxin B VHH-1Biological
Components of LMN-201
LMN-201 Anti-toxin B VHH-2Biological
Components of LMN-201
LMN-201 Anti-toxin B VHH-3Biological
Components of LMN-201
LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3Biological
Components of LMN-201
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Presence of Capsules and/or Transit Markers in Ostomy Fluid by Visual ObservationTime frame: Arrival (baseline), Predose (immediately before dosing), and up to 12 hours post dose.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Wesley Medical Research Limited
Auchenflower, Queensland, Australia
Coastal Digestive Health
Maroochydore, Queensland, Australia
Coral Sea Clinical Research Institute
North Mackay, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.